- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00103519
Study of DITPA in Patients With Congestive Heart Failure
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of DITPA in Patients With NYHA Class III and IV Congestive Heart Failure Who Have Low Serum T3 Levels
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Congestive heart failure (CHF) is a major public health problem associated with significant morbidity and mortality in patients with New York Heart Association (NYHA) class III or IV disease. Multiple studies have identified a particularly high-risk group of patients who have reduced thyroid hormone activity, specifically, low serum triiodothyronine (T3) levels. This group represents approximately 30% of patients with NYHA class III or IV disease and has significantly higher mortality rates than those with normal T3.
DITPA (3,5-diiodothyropropionic acid) is an analogue of naturally occurring thyroid hormone (T3) that has been specifically designed to improve cardiac performance with a lower potential for tachycardia in CHF patients. Although structurally similar to T3, DITPA has a propionic acid side chain and lacks an iodine at the 3' position of the outer phenolic ring. While DITPA binds to the same thyroid hormone receptors as T3, binding affinities are significantly less, suggesting partial agonistic actions. Preclinical studies with DITPA have supported a rationale for its use in patients with CHF.
Primary objective: To assess the safety and tolerability of DITPA in patients with NYHA class III/IV CHF and low serum T3.
Secondary Objective: To obtain preliminary evidence of the efficacy of DITPA in patients with NYHA class III/IV CHF and low serum T3
Design: The multi-center, randomized, double-blind, placebo-controlled study is designed to evaluate the safety and tolerability of DITPA in patients with NYHA class III or IV CHF who have low levels of serum T3 with normal levels of thyroid stimulating hormone (TSH).
One hundred and fifty patients at approximately 35 centers in the U.S. will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio (i.e., 50 patients per treatment group):
- DITPA at 180 mg/day (90 mg twice a day [BID], orally)
- DITPA at 360 mg/day (180 mg BID, orally)
- Placebo BID, orally
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Huntsville, Alabama, United States, 35806
- The Heart Center
-
-
Arizona
-
Peoria, Arizona, United States, 85381
- Cardiac Solutions
-
Tucson, Arizona, United States, 85724
- University of Arizona Sarver Heart Center
-
-
California
-
Los Angeles, California, United States, 90033
- University of Southern California
-
Los Angeles, California, United States, 90095
- UCLA Medical Center
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
Walnut Creek, California, United States, 94598
- Cardiovascular Consultants Medical Group
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Saint Joseph's Research Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71103
- Louisiana State University Health Science Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10032
- Columbia University New York Presbyterian Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45220
- Cincinnati VA Medical Center
-
Cleveland, Ohio, United States, 44195
- Clevaland Clinic Foundation
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73120
- Oklahoma Foundation for Cardiovascular Research
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health Sciences University
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Milton S. Hershey Medical Center
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75226
- Baylor University Medical Center Heart Place
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- The University of Virginia Health System
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- William S. Middleton Memorial Veterans Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Greater than or equal to 18 years of age
- NYHA class III or IV CHF
- Females must not be pregnant or lactating. Females of childbearing potential and males must use a reliable means of contraception
- Serum total T3 <= 95 ng/dL with normal levels of TSH
- On a regimen consisting of angiotensin-converting enzyme inhibitors and/or angiotensin receptor antagonists, beta blockers, and diuretics for a minimum of 3 months prior to randomization
- Clinically stable for 2 weeks prior to randomization (defined as no change in functional class by NYHA, no hospitalization or ER visit, and no intravenous inotropic or vasodilator treatment for 2 weeks)
- An LVEF <= 40%, documented within 6 months prior to randomization, or > 6 months with confirmation of LVEF by local echocardiographic measurements within 2 weeks prior to randomization
- Able to give informed consent
Exclusion Criteria:
- New onset CHF (less than 3 months prior to randomization)
- Active myocarditis, hypertrophic cardiomyopathy, uncorrected primary valvular disease, restrictive cardiomyopathy, uncorrected congenital heart disease, or constrictive pericarditis
- Myocardial infarction, unstable ischemic heart disease, stroke, or coronary revascularization procedure within 4 weeks prior to randomization; or an expectation of a coronary revascularization procedure, cardiac transplant, or left ventricular assist device placement being needed within 24 weeks after randomization
- History of sudden arrhythmic syncope or sustained ventricular arrhythmia, unless the patient has an implantable cardioverter defibrillator (ICD) for at least 12 weeks prior to randomization; history of clinically significant heart block, unless the patient has had a pacemaker at least 12 weeks prior to randomization
- History of cardiac resynchronization therapy in the last 12 weeks prior to randomization or expectation of cardiac resynchronization therapy or ventricular mechanical assistance needed within 24 weeks after randomization
- History of cardiac transplant
- Heart rate < 50 beats per minute or > 130 beats per minute
- Systolic blood pressure <= 80 mm Hg
- Serum creatinine => 2.5 mg/dL
- Treatment with intravenous vasodilators (including nesiritide) or inotropes within 2 weeks prior to randomization
- Receipt of any other investigational agent or device within 4 weeks prior to randomization
- Diagnosis of other non-cardiac underlying medical conditions expected to impact their mortality within 24 weeks after randomization
- Drug or alcohol dependence, or other conditions which may affect study compliance
- History of thyroid disorders of any form within 24 weeks prior to randomization
- Use of thyroid supplements (levothyroxine, liothyronine, etc.) or any preparation containing thyromimetic agents within 24 weeks prior to randomization
- Supraventricular arrhythmia refractory to conventional treatment, as judged by the investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo BID
|
Placebo
|
Experimental: DITPA 180 mg/day
DITPA 180 mg/day BID
|
|
Experimental: DITPA 360 mg/day
DITPA 360 mg/day BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety and tolerability of DITPA
|
Secondary Outcome Measures
Outcome Measure |
---|
Efficacy of DITPA
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Milton Packer, MD, UT Southwestern Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DIT-803
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure, Congestive
-
Adnan Kastrati, MDBiotronik SE & Co. KGCompleted
-
Signature Medical, Inc.WithdrawnHeart Failure,Congestive
-
Echosense Ltd.WithdrawnCongestive Heart Failure (CHF)United States
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...TerminatedCongestive Heart Failure (CHF)Russian Federation
-
Meir Medical CenterUnknown
-
Nihon KohdenTerminatedHeart Failure,CongestiveUnited States
-
ELA Medical, Inc.Approved for marketing
-
Abbott Medical DevicesCompletedCongestive Heart Failure TreatedItaly
-
Echosense Ltd.Terminated
-
Magenta Medical Ltd.TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart FailureCroatia, Belgium, Serbia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States